Compare Stocks: RXRX, CGON, PTCT, and XENE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$72.42 +1.4%	$66.58	$23.65 ▼ $77.00	$6.39B	0.23	940,442 shs	922,743 shs
PTCT PTC Therapeutics	$69.21 +0.2%	$77.56	$43.17 ▼ $90.87	$5.77B	0.56	1.38 million shs	1.10 million shs
RXRX Recursion Pharmaceuticals	$3.17 -4.2%	$3.33	$2.77 ▼ $7.18	$1.75B	1.03	20.36 million shs	17.42 million shs
XENE Xenon Pharmaceuticals	$64.30 +0.5%	$59.87	$32.78 ▼ $72.66	$6.19B	0.62	1.12 million shs	609,513 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	+1.43%	+4.77%	+4.56%	+4.68%	+168.82%
PTCT PTC Therapeutics	+0.16%	-7.09%	-19.00%	+7.32%	+35.41%
RXRX Recursion Pharmaceuticals	-4.23%	+6.73%	-19.95%	-3.06%	-42.68%
XENE Xenon Pharmaceuticals	+0.45%	+1.90%	+6.21%	+14.82%	+86.92%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$72.42 +1.4%	$66.58	$23.65 ▼ $77.00	$6.39B	0.23	940,442 shs	922,743 shs
PTCT PTC Therapeutics	$69.21 +0.2%	$77.56	$43.17 ▼ $90.87	$5.77B	0.56	1.38 million shs	1.10 million shs
RXRX Recursion Pharmaceuticals	$3.17 -4.2%	$3.33	$2.77 ▼ $7.18	$1.75B	1.03	20.36 million shs	17.42 million shs
XENE Xenon Pharmaceuticals	$64.30 +0.5%	$59.87	$32.78 ▼ $72.66	$6.19B	0.62	1.12 million shs	609,513 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	+1.43%	+4.77%	+4.56%	+4.68%	+168.82%
PTCT PTC Therapeutics	+0.16%	-7.09%	-19.00%	+7.32%	+35.41%
RXRX Recursion Pharmaceuticals	-4.23%	+6.73%	-19.95%	-3.06%	-42.68%
XENE Xenon Pharmaceuticals	+0.45%	+1.90%	+6.21%	+14.82%	+86.92%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGON CG Oncology	2.71	Moderate Buy	$81.73	12.85% Upside
PTCT PTC Therapeutics	2.79	Moderate Buy	$95.75	38.35% Upside
RXRX Recursion Pharmaceuticals	2.20	Hold	$8.10	155.52% Upside
XENE Xenon Pharmaceuticals	3.00	Buy	$77.20	20.06% Upside

Current Analyst Ratings Breakdown

Latest RXRX, CGON, PTCT, and XENE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2026	PTCT PTC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
7/31/2026	PTCT PTC Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$93.00 ➝ $104.00
7/31/2026	PTCT PTC Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$93.00 ➝ $106.00
7/29/2026	CGON CG Oncology	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$100.00
7/20/2026	PTCT PTC Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$95.00 ➝ $93.00
7/17/2026	CGON CG Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	RXRX Recursion Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/16/2026	PTCT PTC Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$124.00 ➝ $130.00
7/7/2026	PTCT PTC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$82.00 ➝ $85.00
7/7/2026	PTCT PTC Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/6/2026	XENE Xenon Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGON CG Oncology	$5.07M	1,259.63	N/A	N/A	$9.33 per share	7.76
PTCT PTC Therapeutics	$1.73B	3.34	$8.79 per share	7.87	($1.98) per share	-34.95
RXRX Recursion Pharmaceuticals	$74.68M	22.49	N/A	N/A	$2.14 per share	1.48
XENE Xenon Pharmaceuticals	$7.50M	828.78	N/A	N/A	$7.53 per share	8.54

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGON CG Oncology	-$160.99M	-$2.33	N/A	N/A	N/A	N/A	-23.33%	-22.24%	8/7/2026 (Estimated)
PTCT PTC Therapeutics	$682.64M	-$0.58	N/A	31.18	1.92	-3.80%	-362.45%	-1.32%	N/A
RXRX Recursion Pharmaceuticals	-$644.76M	-$1.20	N/A	N/A	N/A	-842.95%	-54.33%	-40.60%	N/A
XENE Xenon Pharmaceuticals	-$345.91M	-$4.70	N/A	N/A	N/A	N/A	-49.23%	-46.42%	8/6/2026 (Estimated)

Latest RXRX, CGON, PTCT, and XENE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2026	Q2 2026	CGON CG Oncology	-$0.6642	N/A	N/A	N/A	$0.36 million	N/A
8/6/2026	Q2 2026	XENE Xenon Pharmaceuticals	-$1.14	N/A	N/A	N/A	$1.67 million	N/A
8/5/2026	Q2 2026	RXRX Recursion Pharmaceuticals	-$0.24	-$0.25	-$0.01	-$0.25	$10.97 million	$7.67 million
7/30/2026	Q2 2026	PTCT PTC Therapeutics	$0.2363	$0.92	+$0.6837	$0.92	$298.63 million	$360.52 million
5/8/2026	Q1 2026	CGON CG Oncology	-$0.58	-$0.71	-$0.13	-$0.71	$0.45 million	$1.08 million
5/7/2026	Q1 2026	PTCT PTC Therapeutics	-$0.45	-$0.03	+$0.42	-$0.03	$217.42 million	$272.55 million
5/7/2026	Q1 2026	XENE Xenon Pharmaceuticals	-$1.17	-$1.17	N/A	-$1.17	$1.36 million	N/A
5/6/2026	Q1 2026	RXRX Recursion Pharmaceuticals	-$0.30	-$0.22	+$0.08	-$0.22	$15.78 million	$6.47 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGON CG Oncology	N/A	31.30	31.25
PTCT PTC Therapeutics	N/A	3.39	3.28
RXRX Recursion Pharmaceuticals	0.01	5.47	5.47
XENE Xenon Pharmaceuticals	N/A	27.79	27.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGON CG Oncology	26.56%
PTCT PTC Therapeutics	N/A
RXRX Recursion Pharmaceuticals	89.06%
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
CGON CG Oncology	4.80%
PTCT PTC Therapeutics	5.30%
RXRX Recursion Pharmaceuticals	6.65%
XENE Xenon Pharmaceuticals	2.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGON CG Oncology	61	88.20 million	83.97 million	Optionable
PTCT PTC Therapeutics	1,410	83.46 million	79.04 million	Optionable
RXRX Recursion Pharmaceuticals	400	529.91 million	494.67 million	Optionable
XENE Xenon Pharmaceuticals	210	96.67 million	93.85 million	Optionable

RXRX, CGON, PTCT, and XENE Headlines

Recent News About These Companies

Xenon Pharma Q2 2026 earnings preview

1 hour ago | msn.com

Xenon Pharmaceuticals Inc. $XENE Shares Bought by Sei Investments Co.

August 4 at 4:40 AM | marketbeat.com

Xenon Pharmaceuticals (XENE) to Release Earnings on Thursday

August 2, 2026 | marketbeat.com

Lazard Asset Management LLC Sells 27,908 Shares of Xenon Pharmaceuticals Inc. $XENE

August 2, 2026 | marketbeat.com

Xenon Pharmaceuticals (NASDAQ:XENE) Rating Increased to Sell at Wall Street Zen

August 1, 2026 | americanbankingnews.com

Xenon Pharmaceuticals (NASDAQ:XENE) Raised to Sell at Wall Street Zen

August 1, 2026 | marketbeat.com

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 31, 2026 | financialpost.comF

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 31, 2026 | globenewswire.com

Janus Henderson Group PLC Boosts Stock Position in Xenon Pharmaceuticals Inc. $XENE

July 31, 2026 | marketbeat.com

Renaissance Technologies LLC Takes $17.47 Million Position in Xenon Pharmaceuticals Inc. $XENE

July 31, 2026 | marketbeat.com

Xenon to Report Q2 2026 Financial Results on August 6, 2026

July 30, 2026 | financialpost.comF

Xenon to Report Q2 2026 Financial Results on August 6, 2026

July 30, 2026 | globenewswire.com

Stempoint Capital LP Sells 207,850 Shares of Xenon Pharmaceuticals Inc. $XENE

July 30, 2026 | marketbeat.com

26,186 Shares in Xenon Pharmaceuticals Inc. $XENE Acquired by SummitTX Capital L.P.

July 30, 2026 | marketbeat.com

Redmile Group LLC Purchases 128,792 Shares of Xenon Pharmaceuticals Inc. $XENE

July 29, 2026 | marketbeat.com

Xenon Pharmaceuticals Inc. $XENE Shares Acquired by ADAR1 Capital Management LLC

July 29, 2026 | marketbeat.com

Xenon Pharmaceuticals Inc. $XENE is Rock Springs Capital Management LP's 9th Largest Position

July 28, 2026 | marketbeat.com

Eversept Partners LP Lowers Holdings in Xenon Pharmaceuticals Inc. $XENE

July 28, 2026 | marketbeat.com

Xenon Pharmaceuticals Inc. $XENE Shares Purchased by Swiss National Bank

July 28, 2026 | marketbeat.com

64,563 Shares in Xenon Pharmaceuticals Inc. $XENE Purchased by Castleark Management LLC

July 28, 2026 | marketbeat.com

Orbimed Advisors LLC Acquires 612,771 Shares of Xenon Pharmaceuticals Inc. $XENE

July 27, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX, CGON, PTCT, and XENE Company Descriptions

CG Oncology NASDAQ:CGON

$72.42 +1.02 (+1.43%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$71.46 -0.97 (-1.33%)

As of 06:10 AM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

PTC Therapeutics NASDAQ:PTCT

$69.21 +0.11 (+0.16%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$69.25 +0.04 (+0.06%)

As of 06:10 AM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Recursion Pharmaceuticals NASDAQ:RXRX

$3.17 -0.14 (-4.23%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$3.18 +0.01 (+0.22%)

As of 07:18 AM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Xenon Pharmaceuticals NASDAQ:XENE

$64.30 +0.29 (+0.45%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$64.52 +0.22 (+0.33%)

As of 04:09 AM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RXRX, CGON, PTCT, and XENE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RXRX, CGON, PTCT, and XENE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RXRX, CGON, PTCT, and XENE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX, CGON, PTCT, and XENE Company Descriptions

CG Oncology NASDAQ:CGON

PTC Therapeutics NASDAQ:PTCT

Recursion Pharmaceuticals NASDAQ:RXRX

Xenon Pharmaceuticals NASDAQ:XENE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RXRX, CGON, PTCT, and XENE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RXRX, CGON, PTCT, and XENE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RXRX, CGON, PTCT, and XENE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX, CGON, PTCT, and XENE Company Descriptions

CG Oncology NASDAQ:CGON

PTC Therapeutics NASDAQ:PTCT

Recursion Pharmaceuticals NASDAQ:RXRX

Xenon Pharmaceuticals NASDAQ:XENE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools